These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 32771101)

  • 1. Further clinical interpretation and implications of KEYNOTE-048 findings.
    Revannasiddaiah S; Devadas SK; Maka VV; Kilara N
    Lancet; 2020 Aug; 396(10248):378. PubMed ID: 32771101
    [No Abstract]   [Full Text] [Related]  

  • 2. Further clinical interpretation and implications of KEYNOTE-048 findings.
    Szturz P; Vermorken JB
    Lancet; 2020 Aug; 396(10248):379. PubMed ID: 32771103
    [No Abstract]   [Full Text] [Related]  

  • 3. Further clinical interpretation and implications of KEYNOTE-048 findings.
    McCaw ZR; Ludmir EB; Kim DH; Wei LJ
    Lancet; 2020 Aug; 396(10248):378-379. PubMed ID: 32771102
    [No Abstract]   [Full Text] [Related]  

  • 4. Keynote 48: Is it really for everyone?
    Schoenfeld JD; Fell G; Haddad RI; Trippa L
    Oral Oncol; 2020 Jun; 105():104762. PubMed ID: 32381470
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pembrolizumab is more effective and better tolerable than methotrexate, docetaxel, or cetuximab in recurrent or metastatic HNSCC (KEYNOTE-040)].
    Hermann RM; Christiansen H
    Strahlenther Onkol; 2019 Sep; 195(9):851-854. PubMed ID: 31250051
    [No Abstract]   [Full Text] [Related]  

  • 6. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
    Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
    Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Cetuximab in combination with radiotherapy or chemotherapy against advanced squamous cell carcinoma of the head and neck.
    Li JZ; Zheng JW; Zhang ZY
    Shanghai Kou Qiang Yi Xue; 2008 Feb; 17(1):1-5. PubMed ID: 18360658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Grading system and management guidelines for dermatitis induced by head and neck radiotherapy plus cetuximab: clinical validation required.
    Langendijk JA; Oosting SF
    Ann Oncol; 2011 Oct; 22(10):2157-9. PubMed ID: 21878428
    [No Abstract]   [Full Text] [Related]  

  • 9. p16 status and choice of chemotherapy in the KEYNOTE-040 study.
    Bins S; Mathijssen RHJ
    Lancet; 2019 Oct; 394(10206):1322-1323. PubMed ID: 31609222
    [No Abstract]   [Full Text] [Related]  

  • 10. p16 status and choice of chemotherapy in the KEYNOTE-040 study.
    Wei W; Ji M; Wu CP; Yang X
    Lancet; 2019 Oct; 394(10206):1321-1322. PubMed ID: 31609221
    [No Abstract]   [Full Text] [Related]  

  • 11. PD-1 inhibition enters the frontline.
    Killock D
    Nat Rev Clin Oncol; 2020 Feb; 17(2):69. PubMed ID: 31729474
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to "Keynote 48: Is it really for everyone?".
    Burtness B; Ge J
    Oral Oncol; 2021 Jan; 112():104983. PubMed ID: 33032941
    [No Abstract]   [Full Text] [Related]  

  • 13. Cetuximab in the treatment of squamous cell carcinoma of the head and neck.
    Specenier P; Vermorken JB
    Expert Rev Anticancer Ther; 2011 Apr; 11(4):511-24. PubMed ID: 21504318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p16 status and choice of chemotherapy in the KEYNOTE-040 study - Authors' reply.
    Cohen EEW; Soulières D; Swaby RF; Harrington KJ
    Lancet; 2019 Oct; 394(10206):1323. PubMed ID: 31609223
    [No Abstract]   [Full Text] [Related]  

  • 15. PD-1 immunotherapy for recurrent or metastatic HNSCC.
    Ferris RL; Licitra L
    Lancet; 2019 Nov; 394(10212):1882-1884. PubMed ID: 31679948
    [No Abstract]   [Full Text] [Related]  

  • 16. Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study.
    Forster MD; Dillon MT; Kocsis J; Remenár É; Pajkos G; Rolland F; Greenberg J; Harrington KJ
    Eur J Cancer; 2019 Dec; 123():36-47. PubMed ID: 31648099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
    Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.
    Kondo N; Tsukuda M; Taguchi T; Nakazaki K; Sakakibara A; Takahashi H; Toth G; Nishimura G
    Cancer Sci; 2011 Sep; 102(9):1717-23. PubMed ID: 21631644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
    Song Q; Li X; Li B
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.
    Rampias T; Giagini A; Siolos S; Matsuzaki H; Sasaki C; Scorilas A; Psyrri A
    Clin Cancer Res; 2014 Jun; 20(11):2933-46. PubMed ID: 24696319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.